Business Context and Reporting Period
Karyopharm Therapeutics Inc. (KPTI) is a commercial-stage pharmaceutical company focused on the development and commercialization of XPO1 inhibitors, primarily its lead asset XPOVIO (selinexor). The company reported for the fiscal year ended December 31, 2025. XPOVIO is approved in the U.S. for multiple myeloma and diffuse large B-cell lymphoma (DLBCL). The company is advancing Phase 3 clinical trials for selinexor in myelofibrosis (SENTRY Trial) and endometrial cancer (XPORT-EC-042 Trial).
Key Financial Metrics
| Metric | 2025 | 2024 |
|---|---|---|
| Total Revenue | $146.1 million | $145.2 million |
| Net Product Revenue (XPOVIO) | $114.9 million | $112.8 million |
| License and Other Revenue | $31.2 million | $32.4 million |
| Net Loss | $(196.0) million | $(76.4) million |
| Loss from Operations | $(90.7) million | $(119.4) million |
| Cash, Cash Equivalents, and Investments | $63.7 million | $108.7 million |
| Accumulated Deficit | $(1.8) billion | $(1.6) billion |
Debt and Liquidity: Following October 2025 financing transactions, the company holds $116.5 million in senior secured term loans, $118.5 million in convertible notes (2028 and 2029 maturities), and $116.2 million in maximum remaining payments under a revenue interest financing agreement. The company maintains a minimum liquidity covenant of $10.0 million through October 2026, increasing to $25.0 million thereafter.
Material Changes vs. Prior Period
- Net Loss Expansion: Net loss increased significantly to $196.0 million in 2025 from $76.4 million in 2024. This was primarily driven by a $62.4 million loss on extinguishment of debt related to refinancing transactions in October 2025, compared to a $44.7 million gain in 2024.
- Revenue Stability: Total revenue remained relatively flat, increasing slightly by 1% year-over-year. Net product revenue grew 2% due to higher net prices, while license revenue decreased 4% due to lower milestone-related revenue from partners other than Menarini.
- Operating Expenses: Total operating expenses decreased by 11% to $236.8 million. Research and development expenses fell 12% to $125.6 million, and selling, general, and administrative expenses fell 9% to $105.2 million, reflecting workforce reductions and cost management initiatives.
- Cash Position: Cash, cash equivalents, and investments decreased by approximately $45 million to $63.7 million, driven by operating cash outflows and reduced investment maturities.
Guidance, Outlook, and Risks
Going Concern: Management has concluded there is substantial doubt regarding the company's ability to continue as a going concern within one year of the financial statement issuance date. Based on current capital resources and operating plans, the company expects to fund operations only into the second quarter of 2026.
Clinical Outlook:
- SENTRY Trial (Myelofibrosis): Enrollment completed in September 2025; top-line data expected in March 2026.
- XPORT-EC-042 Trial (Endometrial Cancer): Enrollment ongoing; top-line data expected in mid-2026. The trial design was modified in 2025 following FDA feedback regarding the evolving treatment landscape.
- EMN29 Trial (Multiple Myeloma): Enrollment completed in Q4 2024; top-line data expected in the second half of 2026.
- DLBCL Confirmatory Trial: The company received a missed milestone communication from the FDA in January 2026 regarding the confirmatory trial for the accelerated DLBCL approval. Continued delays could result in withdrawal of this approval.
Strategic Actions: The company is evaluating strategic alternatives, including equity offerings, debt refinancing, collaborations, or a potential sale of the company. A special meeting of stockholders is scheduled for February 18, 2026, to seek approval for an increase in authorized shares to facilitate future capital raises.
Investor Verification Checklist
- Cash Runway: Verify the specific timeline for cash depletion and the status of any new financing agreements post-filing.
- Debt Covenants: Confirm compliance with the minimum liquidity covenant ($10.0 million through Oct 2026, then $25.0 million) and interest payment schedules (payable in-kind through March 2026).
- DLBCL Approval Status: Monitor FDA communications regarding the confirmatory trial for the DLBCL indication, as withdrawal of this approval could impact global partners.
- Stockholder Vote: Track the outcome of the February 18, 2026, special meeting regarding the increase in authorized shares, which is critical for future equity financing.
- Clinical Data Readouts: Watch for the March 2026 SENTRY trial data and mid-2026 XPORT-EC-042 data, which are pivotal for future revenue growth and valuation.